SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 47 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $392 | -30.6% | 27,000 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $565 | -64.1% | 27,000 | -63.9% | 0.00% | 0.0% |
| Q1 2023 | $1,575 | +148.8% | 74,700 | +200.0% | 0.00% | -33.3% |
| Q4 2022 | $633 | -99.9% | 24,900 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $598,000 | +24.8% | 24,900 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $479,000 | +17.4% | 24,900 | +6.0% | 0.00% | +100.0% |
| Q1 2022 | $408,000 | +3038.5% | 23,500 | +1466.7% | 0.00% | – |
| Q4 2017 | $13,000 | -23.5% | 1,500 | 0.0% | 0.00% | – |
| Q3 2017 | $17,000 | -15.0% | 1,500 | 0.0% | 0.00% | – |
| Q2 2017 | $20,000 | 0.0% | 1,500 | 0.0% | 0.00% | – |
| Q1 2017 | $20,000 | +100.0% | 1,500 | 0.0% | 0.00% | – |
| Q4 2016 | $10,000 | -54.5% | 1,500 | 0.0% | 0.00% | – |
| Q3 2016 | $22,000 | +46.7% | 1,500 | -6.2% | 0.00% | – |
| Q2 2016 | $15,000 | – | 1,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
| Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
| Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
| ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
| COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
| SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
| Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
| HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |